Illumina announced this week the launch of its iScan System, a next-generation microarray scanner that the company claims can provide researchers conducting genotyping and gene expression studies “greater throughput, enhanced automation, and improved ease of use” than its older BeadStation system.
According to the company, when the iScan System is used with Illumina's recently launched Infinium High-Density Human1M-Duo and Human610-Quad Genotyping BeadChips, and its laboratory information management systems and automation options, the system can complete genotyping studies up to six times faster than studies run on its BeadStation.
"Using our multi-sample iSelect BeadChip, researchers can process 120 samples in just 60 minutes," said Illumina CEO Jay Flatley in a statement. Additionally, utilizing sub-micron resolution, assay automation, and laboratory information management systems options, researchers can produce up to 225 million genotypes per day with one scanner, the company said.
The iScan System is available to academic researchers and to industry through an early access program. So far, Illumina's customers for the new system include Scripps Genomics Medicine and Translational Science Institute and Cogenics, a division of Clinical Data. Full commercialization of the system will begin in the second quarter.
Researchers at Scripps Genomics Medicine and Translational Science Institute are using the iScan System to identify genetic determinants of cardiovascular disease and develop diagnostics. “After scanning fewer than 100 BeadChips, Scripps researchers have reported call rates averaging 99.8 percent, which are consistent with Illumina's existing high call rates for the BeadStation,” Illumina said.